NASDAQ$SANA
Sana Biotechnology Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Sana Biotechnology reported financial results for the third quarter of 2022 and provided business updates.
Sana Biotechnology reported a net loss of $85.1 million for the third quarter of 2022. The company's cash position remains strong at $511.6 million, which is expected to fund operations into 2025. Key programs like SC291 and SG295 are progressing, with IND filings expected in the near future.
- Sana Biotechnology remains on track to file an IND for SC291 this year, with potential clinical data expected in 2023.
- The company is developing a second-generation process for SG295, which is expected to improve potency, safety, and manufacturability, with an IND filing anticipated in 2023.
- Sana Biotechnology is advancing its SC276 program, with an IND filing expected in 2023, targeting B cell malignancies.
- The company's cash position was $511.6 million as of September 30, 2022, providing a cash runway into 2025.
Headline financials
Revenue & EPS history
Sana · Revenue · Quarterly
$0
Forward guidance
Sana Biotechnology anticipates several milestones in the near future, including IND filings for SC291, SG295, and SC276, along with potential clinical data readouts. The company's focus remains on advancing its pipeline and platforms while maintaining a strong balance sheet.
Tailwinds
- SC291: IND filing expected this year.
- SC291: Potential clinical data in 2023, including tumor response and CAR T cell persistence data.
- SG295: IND filing expected in 2023.
- SG295: Second-generation process with improved potency, safety, and manufacturability.
- SC276: IND filing expected in 2023.
Headwinds
- SG295: IND filing delayed until 2023 due to implementation of the second-generation process.
- SC451: IND filing now expected in 2024, with early clinical data also in 2024.
- Research and development expenses increased due to personnel-related expenses, third-party manufacturing costs, and facility costs.
- General and administrative expenses increased due to operating costs associated with the Fremont facility and stock-based compensation expense.
- Net loss for the quarter was $85.1 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-1.2%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+4.1%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+22.3%
Q2 2022
Best reaction
-25.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.5% | -15.3% | -18.6% | |
| Q3 2025 | -0.2% | +3.9% | +25.7% | |
| Q2 2025 | +7.3% | +14.0% | +16.4% | |
| Q1 2025 | +0.6% | -1.7% | +56.9% | |
| Q4 2024 | -17.7% | -16.6% | -40.4% | |
| Q3 2024 | -6.8% | -14.2% | -25.8% | |
| Q1 2024 | -25.3% | -21.2% | -30.5% | |
| Q4 2023 | +5.6% | -8.1% | -6.3% | |
| Q3 2023 | -14.8% | -10.3% | -4.1% | |
| Q2 2023 | -3.8% | -1.3% | -4.5% | |
| Q1 2023 | +7.2% | +11.8% | +8.9% | |
| Q4 2022 | +2.3% | +2.3% | +51.8% | |
| Q3 2022 | -14.1% | -21.6% | -22.2% | |
| Q2 2022 | +22.3% | +18.3% | -3.0% | |
| Q1 2022 | -5.6% | -11.9% | -11.4% | |
| Q4 2021 | +21.1% | +19.5% | +45.6% | |
| Q3 2021 | -5.7% | -3.3% | -19.2% | |
| Q2 2020 | +10.2% | +9.5% | +40.5% | |
| Q2 2021 | +10.2% | +9.5% | +40.5% | |
| Q1 2021 | -13.1% | -1.9% | +9.9% | |
| Q4 2020 | -5.7% | -4.1% | -23.7% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro